Topical 0.4% Ketorolac and Vitreoretinal Surgery
Information source: Emory University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Surgery
Intervention: Ketorolac (Drug)
Phase: Phase 2/Phase 3
Sponsored by: Emory University
Official(s) and/or principal investigator(s):
Stephen J Kim, MD, Principal Investigator, Affiliation: Emory University
To determine whether use of topical 0. 4% ketorolac has any effect on pupil size during
Official title: Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-Controlled, Double-Masked Study
Study design: Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Change in pupil size during vitreoretinal surgery
Secondary outcome: Postoperative pain and inflammation
Other outcomes will be to assess postoperative pain and inflammation and visual acuity.
Minimum age: 18 Years.
Maximum age: N/A.
- Age of 18, routine elective vitrectomy
- history of trauma, uveitis, prior intraocular surgery within 3 months, requirement of
mechanical pupil dilation, prior inclusion of other eye
Locations and Contacts
Emory Eye Clinic, Atlanta, Georgia 30322, United States
Starting date: November 2006
Ending date: October 2007
Last updated: December 17, 2007